Michael Mandola News Today

Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme Bristol Myers Squibb today announced an update on CheckMate -548, a Phase 3 trial evaluating the addition of Opdivo to the current standard of care versus placebo plus the standard of care in patients with newly diagnosed glioblastoma multiforme with O6-methylguanine-DNA methyltransferase promoter methylation following surgical resection of the t...

Bristol-Myers: Phase 3 CheckMate -548 Trial Will Not Meet Primary Endpoint Of Overall Survival NEW YORK CITY (dpa-AFX) - Biopharmaceutical company Bristol Myers Squibb Co. (BMY) said Wednesday that following a routine review of the CheckMate -548 Phase 3 trial by an independent data monitoring committee or DMC, the company was informed that based on the number of events to date, the study will not meet its primary endpoint of overall survival in patients with no baseline corticosteroid use or i...

Bristol-Myers Squibb  ( BMY) - Get Report said on Wednesday that its glioblastoma cancer treatment Opdivo failed to meet its goals in a Phase 3 trial. “Following a routine review of the study by an independent data-monitoring committee, Bristol-Myers Squibb was informed that based on the number of events to date, the study will not meet its primary endpoint of overall survival in patients with no baseline corticosteroid use or in the overall randomized population,” the company said in a s...